Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.25 (4.57%)
Data as of 11/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
11/25/15Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive MelanomaPrinter Friendly Version
11/21/15Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC™ in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International CongressPrinter Friendly Version
11/12/15Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17Printer Friendly Version
11/10/15Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2014 Annual Report (pdf)
Download Documentation2013 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.